The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease

Background: Dopamine agonists are useful drugs for the management of patients with Parkinson's disease in the early stages and in later stages of the disease. Parkinson's disease is a progressive neurodegenerative disease that primarily affects dopamine-producing nerve cells in the brain. They bind to dopamine receptors in nerve cells that regulate body movement and motor function. Electroanalytical methods are used in medicinal, clinical and pharmaceutical research. The voltammetry is one of the most commonly used electroanalytical methods. The aims of this review are to gather and discuss studies of voltammetric methods used in determination of dopamine agonists. Method: This review includes the use of various voltammetric methods for determination studies of dopamine agonists from pharmaceutical dosage forms and biological samples. These studies were examined in terms of used voltammetric method or methods, working electrode, buffer, pH and validation parameters. Results: Cabergoline, pramipexole, ropinirole have more studies, while bromocriptine and apomorphine have fewer studies in the literature. Differential pulse voltammetry and square wave voltammetry methods were the most applied methods for determination of dopamine agonist drugs from pharmaceuticals and biological samples. But, stripping, cyclic and lineer sweep voltammetry methods are less applied methods. In this studies, a lot of modified electrodes were developed and used to analyse of dopamine agonists. Conclusion: The voltammetric methods supply determination of therapeutic agents and/or their metabolites in clinical samples at extremely low concentrations without the necessity for the sample pre-treatment or time consuming extraction steps. Also the modified electrodes and validated voltammetric methods provide good stability, repeatability, reproducibility and high recovery for the analysis of the analyte.

Download Full-text

Early Parkinson's disease: dopamine agonists have increasingly important role in symptom management

Drugs & Therapy Perspectives ◽

10.2165/00042310-200117170-00002 ◽

2001 ◽

Vol 17 (17) ◽

pp. 5-9

Author(s):

&NA;

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Symptom Management ◽

Dopamine Agonists ◽

Early Parkinson’S Disease

Download Full-text

The use of dopamine agonists in newly diagnosed Parkinson's disease patients has changed

European Geriatric Medicine ◽

10.1016/j.eurger.2014.05.003 ◽

2014 ◽

Vol 5 (5) ◽

pp. 357-358

Author(s):

H. Kuusisto ◽

P. Hujanen ◽

T. Mattila ◽

T. Luukkaala ◽

T. Keränen

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dopamine Agonists ◽

Newly Diagnosed

Download Full-text

Dopamine agonists for parkinson’s disease

Drug and Therapeutics Bulletin ◽

10.1136/dtb.29.2.7 ◽

1991 ◽

Vol 29 (2) ◽

pp. 7-8

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Side Effects ◽

Therapeutic Efficacy ◽

Dopamine Agonists ◽

Dopa Decarboxylase ◽

Decarboxylase Inhibitor ◽

Duration Of Action ◽

Motor Disability ◽

The Uk

Bromocriptine, lysuride (formerly lisuride, Revanil – Roche) and pergolide (not yet marketed in the UK) are dopamine agonists developed for use in the treatment of patients with Parkinson’s disease. Combination of a dopamine agonist with levodopa plus a dopa-decarboxylase inhibitor (‘co-dieldopa’)* may have advantages at all stages of the disease. The aim of combined co-dieldopa + agonist treatment is to limit some of the problems with prolonged co-dieldopa use alone; especially fluctuations in motor disability.1 It is still not clear how the three agonists compare with each other for therapeutic efficacy, duration of action, and side effects, nor how they are best combined with co-dieldopa.

Download Full-text